BR112022020825A2 - Análogos de nucleosídeos bicíclicos e monocíclicos para o tratamento de hepatite e - Google Patents

Análogos de nucleosídeos bicíclicos e monocíclicos para o tratamento de hepatite e

Info

Publication number
BR112022020825A2
BR112022020825A2 BR112022020825A BR112022020825A BR112022020825A2 BR 112022020825 A2 BR112022020825 A2 BR 112022020825A2 BR 112022020825 A BR112022020825 A BR 112022020825A BR 112022020825 A BR112022020825 A BR 112022020825A BR 112022020825 A2 BR112022020825 A2 BR 112022020825A2
Authority
BR
Brazil
Prior art keywords
bicyclic
hepatitis
treatment
nucleoside analogs
monocyclic nucleoside
Prior art date
Application number
BR112022020825A
Other languages
English (en)
Portuguese (pt)
Inventor
Hugo Maria Jonckers Tim
Pauwels Frederik
DEBING Yannick
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of BR112022020825A2 publication Critical patent/BR112022020825A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BR112022020825A 2020-04-14 2021-04-13 Análogos de nucleosídeos bicíclicos e monocíclicos para o tratamento de hepatite e BR112022020825A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20169480 2020-04-14
PCT/EP2021/059504 WO2021209419A1 (en) 2020-04-14 2021-04-13 Bi- and monocyclic nucleoside analogs for treatment of hepatitis e

Publications (1)

Publication Number Publication Date
BR112022020825A2 true BR112022020825A2 (pt) 2022-11-29

Family

ID=70289599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020825A BR112022020825A2 (pt) 2020-04-14 2021-04-13 Análogos de nucleosídeos bicíclicos e monocíclicos para o tratamento de hepatite e

Country Status (15)

Country Link
EP (1) EP4135715B1 (cg-RX-API-DMAC7.html)
JP (2) JP2023522615A (cg-RX-API-DMAC7.html)
KR (1) KR20230002592A (cg-RX-API-DMAC7.html)
CN (1) CN115515603A (cg-RX-API-DMAC7.html)
AR (1) AR121836A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021255809B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022020825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174790A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002804A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982564T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022012904A (cg-RX-API-DMAC7.html)
PE (1) PE20230386A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552679A1 (cg-RX-API-DMAC7.html)
UY (1) UY39172A (cg-RX-API-DMAC7.html)
WO (1) WO2021209419A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086592A2 (en) * 2022-10-17 2024-04-25 Emory Unversity 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2025014360A1 (en) * 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952714T3 (es) * 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
US9603864B2 (en) * 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) * 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2017210438A1 (en) * 2016-06-03 2017-12-07 Gilead Pharmasset Llc Methods of treating hepatitis e viral infection

Also Published As

Publication number Publication date
CA3174790A1 (en) 2021-10-21
US20230310481A1 (en) 2023-10-05
EP4135715A1 (en) 2023-02-22
CL2022002804A1 (es) 2023-03-31
AU2021255809B2 (en) 2026-08-06
CN115515603A (zh) 2022-12-23
PH12022552679A1 (en) 2024-04-22
EP4135715B1 (en) 2024-05-08
ES2982564T3 (es) 2024-10-16
MX2022012904A (es) 2023-01-24
AU2021255809A1 (en) 2022-12-15
PE20230386A1 (es) 2023-03-06
UY39172A (es) 2021-10-29
EP4135715C0 (en) 2024-05-08
WO2021209419A1 (en) 2021-10-21
AR121836A1 (es) 2022-07-13
KR20230002592A (ko) 2023-01-05
JP2023522615A (ja) 2023-05-31
JP2026120528A (ja) 2026-07-22

Similar Documents

Publication Publication Date Title
CL2020001146A1 (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CO2022018715A2 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CR20220236A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
CL2020001145A1 (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb).
ECSP13010937A (es) Compuestos antivirales
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
UY37998A (es) Agentes antivirales contra la hepatitis b
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
BR112015031763A2 (pt) Compostos, composição farmacêutica e processos para melhorar ou tratar infecção viral e para inibir a replicação de paramixovírus e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
ECSP21031085A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
CL2021001116A1 (es) Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
CO2020008887A2 (es) Inhibidores de pi4kiiiβ
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
BR112021002565A8 (pt) Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto
CL2022002804A1 (es) Análogos del nucleósido bicíclico y monocíclico para el tratamiento de la hepatitis e.
BR112022005449A2 (pt) Compostos antibacterianos
BR112022005068A2 (pt) Compostos antibacterianos de 4-quinolinona
UY38435A (es) Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
BR112022020820A2 (pt) Análogos de nucleosídeos alquinílicos para o tratamento de hepatite e
BR112022020810A2 (pt) Análogos de nucleosídeos espirocíclicos para o tratamento de hepatite e

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]